Brazil Clears Trials of Vivax Malaria Vaccine
12 Articles
12 Articles
UFMG develops an unprecedented vaccine against malaria A vaccine developed in Brazil against the most common type of malaria in the country has received authorization from the National Agency for Health Surveillance (Anvisa) to begin testing in humans. Battada de Vivaxin, the candidate is the result of a partnership between researchers from the Federal University of Minas Gerais (UFMG), the University of São Paulo (USP) and the pharmaceutical la…
Vaccine seeks to combat malaria vivax, the most common type in Brazil and for which there is not yet an approved immunizer in the world
Brazil’s National Health Surveillance Agency (Anvisa) authorized the initiation of clinical trials, initially with 48 volunteers, of a malaria vaccine developed by Brazilian scientists, reported on Wednesday. The vaccine, known as Vivaxin, has the potential to prevent the most common type of malaria in Latin America, Plasmodium vivax, [...]
A Brazilian vaccine against malaria developed by UFMG received authorization from the National Agency of Health Surveillance (Anvisa) to begin testing in humans. Vivaxin is developed by CTVacinas, from the university, in partnership with USP and the laboratory Cristália. The guarantee allows the start of the candidate's phase 1 tests, aimed at [...] The post UFMG malaria vaccine receives approval from Anvisa for human tests appeared first in BHA…
The immunizer developed by UFMG, USP and the Cristália laboratory seeks to stop the parasite that causes more than 60% of the infections in Latin America.
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
